Crossmark

The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data

Crossref DOI link: https://doi.org/10.1186/s12885-019-6209-9

Published Online: 2019-10-26

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fernández-Navarro, Pablo http://orcid.org/0000-0001-9427-2581
López-Nieva, Pilar http://orcid.org/0000-0001-6369-2444
Piñeiro-Yañez, Elena http://orcid.org/0000-0003-2773-2343
Carreño-Tarragona, Gonzalo http://orcid.org/0000-0002-9570-5542
Martinez-López, Joaquín

Sánchez Pérez, Raúl

Aroca, Ángel

Al-Shahrour, Fátima http://orcid.org/0000-0003-2373-769X
Cobos-Fernández, María Ángeles

Fernández-Piqueras, José http://orcid.org/0000-0003-4520-6785
Funding

Funding for this research was provided by:

Ministerio de Ciencia e Innovación (RTI2018-093330-B_100)

Ministerio de Economía y Competitividad (SAF2015-70561-R, BES-2013-065740)

Fundación Ramón Areces (CIVP19S7917)

Comunidad de Madrid (B2017/BMD-3778; LINFOMAS-CM)

Fundación Científica Asociación Española Contra el Cáncer (AECC, 2018; PROYE18054PIRI)

Instituto de Salud Carlos III (ACCI-CIBERER-17)
License Information

Text and Data Mining valid from 2019-10-26

Version of Record valid from 2019-10-26
More Information

Article History

Received: 13 June 2019

Accepted: 25 September 2019

First Online: 26 October 2019

Ethics approval and consent to participate

: Patients provided written informed consent before study enrollment. The inform consent form was reviewed and approved by Institutional review board from the Research Ethics Committee of Autonomous University of Madrid (previous references are CEI 31–773 and CEI-70-1260). The participant and/or their parents had already provided written informed consent with the guiding principles of the Declaration of Helsinki.

: Not Applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below